Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)

NCT05535192 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT05535192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
March 20, 2023
Completion date
February 1, 2028
Enrollment
270 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, stage i breast cancer, stage ii breast cancer, stage iii breast cancer